Let's Talk Innovation

Let's Talk

You are here

Three Of Our Collaborating Companies Make Fierce Biotech’s 2014 Fierce 15 List

Innovation Center September 22nd, 2014

Today, Fierce Biotech published its 2014 Fierce 15 list, the 12th annual review of the top 15 private biotech companies.

We are excited that three of our collaborating companies are included on this year’s list: (2) Auduro BioTech, Inc., (9) Molecular Partners, and (10) Navitor Pharmaceuticals

Earlier this year, Johnson & Johnson Innovation and Janssen Biotech announced that we entered into an agreement with Auduro BioTech granting Janssen Biotech an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer.  Through a separate agreement, Aduro granted Janssen exclusive rights to Aduro’s ADU741 technology for prostate cancer.

In 2007, along with Index Ventures, Johnson & Johnson Development Corporation was one of the first investors to back Molecular Partners, which works with small proteins called DARPins that can be selected to bind to a given target molecule. In 2011, we announced that Janssen Biotech entered into a strategic research collaboration and option agreement with Molecular Partners to research, discover and develop DARPin associated products for the treatment of immunological diseases. 

And just this past June, Johnson & Johnson Development Corporation, in collaboration with Johnson & Johnson Innovation, was among a group of investors to lead Navitor Pharmaceuticals’ $23.5 million Series A round.  Navitor, which is among our Janssen Labs @ LabCentral community in Cambridge, Mass., is developing highly specific modulators of mTORC1, the pathway primarily responsible for cells’ response to nutrient availability including cell growth and function. Navitor is leveraging the central importance of the mTORC1 pathway to develop new therapies for metabolic diseases, like diabetes, as well as autoimmune, musculoskeletal and other disease areas.

We are proud of all of the companies that we support, but are particularly pleased today to share this special recognition for these three companies whose innovations are helping to advance transformative healthcare products.

Add new comment

Leave a comment

You agree that the information you provide will be governed by our Privacy Policy.
Your email address and last name will not be displayed publicly with your comment.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

We reserve the right to not post any comment that is considered inappropriate, off-topic, abusive, or that is used to promote and solicit for third party sites, initiatives, or products. All comments will be reviewed and may not be posted if deemed inappropriate. Approved comments may take up to 72 hours after they are received to be posted.

This Blog is not intended to be a place to report customer service, adverse events or product quality complaints. We take adverse events and product quality complaints very seriously. To report an adverse event or product quality complaint, please send us a message at jnjinnovation@its.jnj.com.